Category: Biotechnology Industry News

Biotechnology industry news, updates, and press releases

Using Biotechnology, CSI, and Zombies to Promote Science Education in one of America’s Most Challenging Regions

This paper examines the creation of a forensic biotechnology program that engages students, promotes science learning beyond the classroom and makes available novel STEM opportunities to an area which previously had little biotechnology educational off…


Debt and Taxes: Marginal Tax Rate Changes, Capital Structure, and Innovative Activity in the Biotechnology Sector

The purpose of this investigation was to examine the association between changes in corporate marginal tax rates (MTRs) and measures of both innovative activity and capital structure among publicly-traded biotechnology firms.  Across a 1980-2010 time frame, a five-year distributed Almon lag model was utilized to assess the effect of annual changes in MTRs upon patenting activity, research and development (R&D) expenditures, cash and short-term investments, debt-to-asset ratios, and debt-to-equity ratios.  Across the 99 biotech firms studied, results suggested that increases in MTRs were significantly associated with marked decreases in patents, R&D expenditures, and cash and other short-term investments.  Additionally, large and statistically significant increases in both debt-to-asset and debt-to-equity ratios were observed with annual increases in MTRs.  While this research can not necessarily discern whether capital structure changes occurred either as an ex-ante response to or an ex-post result of MTR increases, the implication of decreased patenting activity warrants continued evaluations of both internal financial decision making and external tax policy.


Characteristics of Great Bioscience Leaders

Good leaders in the biosciences share multiple characteristics, starting with certain personality traits – some that are particularly unique and important to the bioscience sector.   They also understand certain concepts, which are necessary for bioscience companies to be successful. 


Industrial Application of Biological Self-healing Concrete: Challenges and Economical Feasibility

Self-healing concrete has been scrutinized by several researchers and some industrial concrete producers in relation to the remediation of the occurrence of micro-cracks. Such cracks are a quite well known problem that can lead to corrosion of the steel reinforcement and thus to the possible failure of the entire concrete structure. The need to repair these cracks as soon as possible leads to maintenance costs which can be of the order of €130 (direct costs) per m3 of concrete. Recent scientific studies indicate that a Microbial Induced Carbonate Precipitation (MICP), using microbial spores as active agent, can be an alternative for the actual repair methods. However, the production of bacterial spores is yet imposing considerable costs. According to some concrete producers they would be willing to pay about €15 to €20 per m3 of concrete for a bio-based self-healing product. However, the actual cost of spores production and encapsulation represent a total cost which is orders of magnitude higher. This article analyzes the costs for the biological self-healing in concrete and evaluates the industrial challenges it faces. There is an urgent need to develop the production of a bio-additive at much lower costs to make the biological self-healing industrial applicable. Axenic production and a possible non-axenic process to obtain ureolytic spores were analyzed and the costs calculations are presented in this paper.


Reverse Stock Splits in the Biotechnology Industry: An Effectuation Approach

Using an effectuation theory lens, we study reverse stock splits in the biotech industry where significant uncertainty makes specific scenarios of success difficult to predict. We conjecture and find that, in contrast to other environments where there is less uncertainty, reverse stock splits in the biotech industry are followed by positive abnormal returns over the subsequent 1- to 12-months. Also consistent with our effectuation-based predictions, we find that these returns are positively related to the reverse split ratio, size, cash holding, and long-term debt, and negatively related to the market-to-book ratio and firm age. We also find that liquidity increases after a reverse stock split. These results suggest that the concept of effectuation theory is better suited to analyzing reverse stock splits in the biotech industry. 


Drug Patent Expirations for December 17 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for December 17 2014

Tradename Applicant Generic Name Patent
Expiration
SANDOSTATIN LAR

Novartis

octreotide acetate

Dec 17, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch database for
complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch database for
complete details

DISCLAIMER:
Although great care
is taken in the proper and correct provision of this service, thinkBiotech
LLC does not accept any responsibility for possible consequences of errors
or omissions in the provided information. There is no warranty that the
information contained herein is error free. Users of this service are
advised to seek professional advice and independent confirmation before
acting on any of the provided information. thinkBiotech LLC reserves the
right to amend, extend or withdraw any part or all of the offered service
without notice.
All trademarks and applicant names are the property
of their respective owners or licensors.


Drug Patent Expirations for December 16 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for December 16 2014

Tradename Applicant Generic Name Patent
Expiration
IONSYS

Incline Therap

fentanyl hydrochloride

Dec 16, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch database for
complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch database for
complete details

DISCLAIMER:
Although great care
is taken in the proper and correct provision of this service, thinkBiotech
LLC does not accept any responsibility for possible consequences of errors
or omissions in the provided information. There is no warranty that the
information contained herein is error free. Users of this service are
advised to seek professional advice and independent confirmation before
acting on any of the provided information. thinkBiotech LLC reserves the
right to amend, extend or withdraw any part or all of the offered service
without notice.
All trademarks and applicant names are the property
of their respective owners or licensors.


Drug Patent Expirations for December 16 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for December 16 2014

Tradename Applicant Generic Name Patent
Expiration
IONSYS

Incline Therap

fentanyl hydrochloride

Dec 16, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch database for
complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch database for
complete details

DISCLAIMER:
Although great care
is taken in the proper and correct provision of this service, thinkBiotech
LLC does not accept any responsibility for possible consequences of errors
or omissions in the provided information. There is no warranty that the
information contained herein is error free. Users of this service are
advised to seek professional advice and independent confirmation before
acting on any of the provided information. thinkBiotech LLC reserves the
right to amend, extend or withdraw any part or all of the offered service
without notice.
All trademarks and applicant names are the property
of their respective owners or licensors.


Drug Patent Expirations for December 15 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for December 15 2014

Tradename Applicant Generic Name Patent
Expiration
RELENZA

Glaxosmithkline

zanamivir

Dec 15, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch database for
complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch database for
complete details

DISCLAIMER:
Although great care
is taken in the proper and correct provision of this service, thinkBiotech
LLC does not accept any responsibility for possible consequences of errors
or omissions in the provided information. There is no warranty that the
information contained herein is error free. Users of this service are
advised to seek professional advice and independent confirmation before
acting on any of the provided information. thinkBiotech LLC reserves the
right to amend, extend or withdraw any part or all of the offered service
without notice.
All trademarks and applicant names are the property
of their respective owners or licensors.


Drug Patent Expirations for December 10 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

DrugPatentWatch -- sales, statistics, drug application information

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for December 10 2014

Tradename Applicant Generic Name Patent
Expiration
OFEV

Boehringer Ingelheim

nintedanib

Dec 10, 2014
WELCHOL

Daiichi Sankyo

colesevelam hydrochloride

Dec 10, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch database for
complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch database for
complete details

DISCLAIMER:
Although great care
is taken in the proper and correct provision of this service, thinkBiotech
LLC does not accept any responsibility for possible consequences of errors
or omissions in the provided information. There is no warranty that the
information contained herein is error free. Users of this service are
advised to seek professional advice and independent confirmation before
acting on any of the provided information. thinkBiotech LLC reserves the
right to amend, extend or withdraw any part or all of the offered service
without notice.
All trademarks and applicant names are the property
of their respective owners or licensors.